Aquestive Therapeutics/AQST

$3.14

10.18%
-
1D1W1MYTD1YMAX

About Aquestive Therapeutics

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. The Company has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs) and excipients in place. Its active programs in its complex molecule pipeline portfolio are: AQST-109-SF and AQST-108-SF. AQST-109-SF (sublingual film) is an orally delivered epinephrine product candidate. AQST-108 is composed of the prodrug dipivefrin which is enzymatically cleaved into epinephrine after administration. Its CNS product candidate, Libervant, is an administered soluble film formulation of diazepam and is its advanced proprietary investigational product candidate. Its licensed products include Suboxone, Exservan, and KYNMOBI.

Ticker

AQST

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Daniel Barber

Employees

130

Headquarters

Warren, United States

AQST Metrics

BasicAdvanced
$171.59M
Market cap
-
P/E ratio
-$0.25
EPS
2.73
Beta
-
Dividend rate

What the Analysts think about AQST

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
101.59% upside
High $10.00
Low $3.00
$3.14
Current price
$6.33
Average price target

AQST Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-15.38% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$13M
-1.52%
Net income
$-2M
-64.91%
Profit margin
-15.38%
-64.38%

AQST Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 73.5%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.23
$0.11
-$0.10
-$0.03
-
Expected
-$0.23
-$0.19
-$0.12
-$0.11
-$0.08
Surprise
-0.35%
-158.2%
-15.25%
-73.5%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Aquestive Therapeutics stock

Buy or sell Aquestive Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing